Evidence for the involvement of the monoaminergic system in the antidepressant-like action of two 4-amine derivatives of 10,11-dihydro-5H-dibenzo [a,d] cycloheptane in mice evaluated in the tail suspension test

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 32, Issue 2, 2008, Pages 368-374

  Duarte, Filipe Silveira ^a   Lach, Gilliard ^a   Martins, Paulo Roberto Codeço ^b   Romeiro, Gilberto Alves ^b   de Lima, Thereza Christina Monteiro ^a  

^a CCB   (Brazil)

^b FLUMINENSE FEDERAL UNIVERSITY   (Brazil)

Author keywords

Depression; Dibenzocyclo heptane derivatives; Monoaminergic mechanisms; Tail suspension test

Indexed keywords

1,2,3,4,8,9 HEXAHYDRODIBENZOCYCLOHEPTANE[4,4A,5 EF]1,4 DIAZEPIN; 10,11 DIHYDRO 5H DIBENZO[A,D]CYCLOHEPTANE; 4 AMINE(3 N,N DIMETHYLPROPYLAMINE) 10,11 DIHYDRO 5H DIBENZO[A,D]CYCLOHEPTANE 5 ONE; CYCLOHEPTANE DERIVATIVE; FENCLONINE METHYL ESTER; FLUOXETINE; HALOPERIDOL; METHYSERGIDE; PRAZOSIN; UNCLASSIFIED DRUG; YOHIMBINE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DEPRESSION; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG MECHANISM; FORCED SWIMMING TEST; IMMOBILIZATION; MALE; MONOAMINERGIC SYSTEM; MOUSE; NONHUMAN;

ANIMALS; ANTIDEPRESSIVE AGENTS; BEHAVIOR, ANIMAL; BIOGENIC MONOAMINES; CYCLOHEPTANES; DEPRESSIVE DISORDER; DISEASE MODELS, ANIMAL; HALOPERIDOL; HINDLIMB SUSPENSION; IMMOBILITY RESPONSE, TONIC; MALE; MICE; MOTOR ACTIVITY;

EID: 38749096307     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2007.08.042     Document Type: Article

References (46)

1. Bai F., Li X., Clay M., Lindstrom T., and Skolnick P. Intra- and interstrain differences in models of "behavioral despair". Pharmacol Biochem Behav 70 (2001) 187-192
2. Bernet S. Prevalence of mental disorders in Europe: results from the European Study of Epidemiology of Mental Disorders (ESEMeD) Project. Acta Psychiatr Scand 110 (2004) 36
3. Blazer D.G., Kessler R.C., McGonagle K.A., and Swartz M.S. The prevalence and distribution of major depression in a national community sample: the National Comorbidity Survey. Am J Psychiatry 151 (1994) 979-986
4. Bourin M., Chenu F., Ripoll N., and David D.J. A proposal of decision tree to screen putative antidepressants using forced swim and tail suspension tests. Behav Brain Res 164 (2005) 266-269
5. Burckhalter H.J., and Korolkovas A. Química Farmacêutica. Guanabara Dois S/A, Rio de Janeiro, R.J. (1982) 223-250
6. Burstein E.S., Ma J., Wong S., Gao Y., Pham E., Knapp A.E., et al. Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist. J Pharmacol Exp Ther 315 (2005) 1278-1287
7. Cervo L., and Samanin R. Clonidine causes antidepressant-like effects in rats by activating alpha 2-adrenoceptors outside the locus coeruleus. Eur J Pharmacol 193 (1991) 309-313
8. Cryan J.F., Markou A., and Lucki I. Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol Sci 23 (2002) 238-245
9. Cryan J.F., Mombereau C., and Vassout A. The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice. Neurosci Biobehav Rev 29 (2005) 571-625
10. Demehri S., Homayoun H., Honar H., Riazi K., Vafaie K., Roushanzamir F., et al. Agmatine exerts anticonvulsant effect in mice: modulation by alpha 2-adrenoceptors and nitric oxide. Neuropharmacology 45 (2003) 534-542
11. Dhingra D., and Sharma A. Antidepressant-like activity of n-hexane extract of nutmeg (Myristica fragrans) seeds in mice. J Med Food 9 (2006) 84-89
12. Duarte F.S., Codeco Martins P.R., Romeiro G.A., and De Lima T.C. Antidepressant-like profile of action of two 4-amine derivatives of 10,11-dihydro-5H-dibenzo [a,d] cycloheptane in mice evaluated in the forced swimming test. Bioorg Med Chem 15 (2007) 1645-1650
13. Elhwuegi A.S. Central monoamines and their role in major depression. Prog Neuropsychopharmacol Biol Psychiatry 28 (2004) 435-451
14. Espejo E.F., and Minano F.J. Prefrontocortical dopamine depletion induces antidepressant-like effects in rats and alters the profile of desipramine during Porsolt's test. Neuroscience 88 (1999) 609-615
15. Goldberg M.R., and Robertson D. Yohimbine: a pharmacological probe for study of the a2-adrenoceptor. Pharmacol Rev 35 (1983) 143-180
16. Greenberg P.E., Kessler R.C., Birnbaum H.G., Leong S.A., Lowe S.W., Berglund P.A., et al. The economic burden of depression in the United States: how did it change between 1990 and 2000?. J Clin Psychiatry 64 (2003) 1465-1475
17. Haapalinna A., Viitamaa T., MacDonald E., Savola J.M., Tuomisto L., Virtanen R., et al. Evaluation of the effects of a specific alpha 2-adrenoceptor antagonist, atipamezole, on alpha 1- and alpha 2-adrenoceptor subtype binding, brain neurochemistry and behaviour in comparison with yohimbine. Naunyn Schmiedebergs Arch Pharmacol 356 (1997) 570-582
18. Holsboer F. Therapeutics for depression and anxiety disorders. Drug Discov Today Ther Strateg 1 (2004) 105-109
19. Kapur S., Vanderspek S.C., Brownlee B.A., and Nobrega J.N. Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy. J Pharmacol Exp Ther 305 (2003) 625-631
20. Kaster M.P., Santos A.R., and Rodrigues A.L. Involvement of 5-HT1A receptors in the antidepressant-like effect of adenosine in the mouse forced swimming test. Brain Res Bull 67 (2005) 53-61
21. Lane E.L., Cheetham S., and Jenner P. Dopamine uptake inhibitor-induced rotation in 6-hydroxydopamine-lesioned rats involves both D1 and D2 receptors but is modulated through 5-hydroxytryptamine and noradrenaline receptors. J Pharmacol Exp Ther 312 (2005) 1124-1131
22. Le A.D., Harding S., Juzytsch W., Funk D., and Shaham Y. Role of alpha-2 adrenoceptors in stress-induced reinstatement of alcohol seeking and alcohol self-administration in rats. Psychopharmacology 179 (2005) 366-373
23. Lehr E. Potential antidepressant properties of pramipexole detected in locomotor and operant behavioral investigations in mice. Psychopharmacology 163 (2002) 495-500
24. Li X., Tizzano J.P., Griffey K., Clay M., Lindstrom T., and Skolnick P. Antidepressant-like actions of an AMPA receptor potentiator (LY392098). Neuropharmacology 40 (2001) 1028-1033
25. Millan M.J., Lejeune F., Gobert A., Brocco M., Auclair A., Bosc C., et al. S18616, a highly potent spiroimidazoline agonist at alpha(2)-adrenoceptors: II. Influence on monoaminergic transmission, motor function, and anxiety in comparison with dexmedetomidine and clonidine. J Pharmacol Exp Ther 295 (2000) 1206-1222
26. Millan M.J., Dekeyne A., Newman-Tancredi A., Cussac D., Audinot V., Milligan G., et al. S18616, a highly potent, spiroimidazoline agonist at alpha(2)-adrenoceptors: I. Receptor profile, antinociceptive and hypothermic actions in comparison with dexmedetomidine and clonidine. J Pharmacol Exp Ther 295 (2000) 1192-1205
27. Minano F.J., Sancibrian M., and Serrano J.S. Hypothermic effect of GABA in conscious restrained rats and its modification by monoaminergic blocking drugs. Methods Find Exp Clin Pharmacol 9 (1987) 225-231
28. Mylecharane E.J. The classification of 5-hydroxytryptamine receptors. Clin Exp Pharmacol Physiol 16 (1989) 517-522
29. Naranjo C.A., Tremblay L.K., and Busto U.E. The role of the brain reward system in depression. Prog Neuropsychopharmacol Biol Psychiatry 25 (2001) 781-823
30. Okuyama S., Sakagawa T., Chaki S., Imagawa Y., Ichiki T., and Inagami T. Anxiety-like behavior in mice lacking the angiotensin II type-2 receptor. Brain Res 821 (1999) 150-159
31. 1B receptors in the mediation of behavior in the forced swim test in mice. Neuropsychopharmacology 24 (2001) 391-398
32. Páez-Pereda M. New drug targets in the signalling pathways activated by antidepressants. Prog Neuropsychopharmacol Biol Psychiatry 29 (2005) 1010-1016
33. Paparrigopoulos T., Psarros C., Bergiannaki J.D., Varsou E., Dafni U., and Stefanis C. Melatonin response to clonidine administration in depression: indication of presynaptic alpha2-adrenoceptor dysfunction. J Affect Disord 65 (2001) 307-313
34. Porsolt R.D., Le Pichon M., and Jalfre M. Depression: a new animal model sensitive to antidepressant treatments. Nature 266 (1977) 730-732
35. Potter W.Z., and Manji H.K. Catecholamines in depression: an update. Clin Chem 40 (1994) 279-287
36. Prins N.H., Van Haselen J.F.W.R., Lefebver R.A., Briejer M.R., Akkermans L.M.A., and Schuurkes J.A.J. Pharmacological characterization of the 5-HT4 receptors mediating relaxation of canine isolated rectum circular smooth muscle. Br J Pharmacol 127 (1999) 1431-1437
37. Romeiro G.A., and Martins P.R.C. Analogues of antidepressants - synthesis of new 4-amine derivatives of 10, 11-dihydro-5H-dibenzo[a,d]-cycloheptane. Heterocycl Commun 7 (2001) 227-232
38. Schramm N.L., McDonald M.P., and Limbird L.E. The alpha(2a)-adrenergic receptor plays a protective role in mouse behavioral models of depression and anxiety. J Neurosci 21 (2001) 4875-4882
39. Stahl S.M., and Grady M.M. Differences in mechanism of action between current and future antidepressants. J Clin Psychiatry 64 (2003) 13-17
40. Stéru L., Chermat R., Thierry B., and Simon P. The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology 85 (1985) 367-370
41. Stone R.A., Barnes P.J., and Fan Chung K. Effect of 5-HTA receptor agonist, 8-OH-DPAT, on cough responses in the conscious guinea pig. Eur J Pharmacol 332 (1997) 201-207
42. Stone E.A., Lin Y., Rosengarten H., Kramer H.K., and Quartermain D. Emerging evidence for a central epinephrine-innervated alpha 1-adrenergic system that regulates behavioral activation and is impaired in depression. Neuropsychopharmacology 28 (2003) 1387-1399
43. Vangveravong S., McElveen E., Taylor M., Xu J., Tu Z., Luedtke R.R., et al. Synthesis and characterization of selective dopamine D2 receptor antagonists. Bioorg Med Chem 14 (2006) 815-825
44. Vetulani J., and Nalepa I. Antidepressants: past, present and future. Eur J Pharmacol 405 (2000) 351-363
45. Winter J.C., and Rabin R.A. Yohimbine as a serotonergic agent: evidence from receptor binding and drug discrimination. J Pharmacol Exp Ther 263 (1992) 682-689
46. Zhang W., and Bymaster F.P. The in vivo effects of olanzapine and other antipsychotic agents on receptor occupancy and antagonism of dopamine D-1, D-2, D-3, 5HT(2A) and muscarinic receptors. Psychopharmacology 141 (1999) 267-278